ArticleOpen forum infectious diseases2025
Patient-Reported Outcomes of Nirmatrelvir Treatment for High-Risk, Nonhospitalized Adults With Symptomatic COVID-19.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04960202 (AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An interventional efficacy and safety, phase 2/3, double-blind, 2-arm study to investigate orally administered pf-07321332/ritonavir compared with placebo in nonhospitalized symptomatic adult participants with covid-19 who are at increased risk of progressing to severe illness
Who cites it
4 citing papers in PubMed.
- Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial.Health and quality of life outcomes · 2026Trial
- Efficacy and Safety of Nirmatrelvir/Ritonavir and Molnupiravir in Non-Hospitalized Patients with COVID-19: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China.Infection · 2026Article
- Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial.Infectious diseases and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nirmatrelvir/ritonavir (NMV/r) is an antiviral treatment for COVID-19. We describe patient-reported outcomes with NMV/r in nonhospitalized adults with COVID-19 at high risk of severe disease. Methods: In a phase 2/3 double-blind study, high-risk adults with SARS-CoV-2 and ≤5 days of symptoms were randomized 1:1 to receive NMV/r or placebo twice daily for 5 days. Patients recorded responses to 3 Global Impression Questions (GIQs) daily through day 28 to assess return to usual health, return to usual activities, and overall severity of COVID-19-related symptoms. The COVID-19-specific Work Productivity and Activity Impairment Questionnaire (WPAI-COVID-19) and EuroQol Quality of Life 5-dimension 5-level scale (EQ-5D-5L) were completed at specified visits through week 24. Results: Compared with placebo, patients receiving NMV/r had a significant 3-day reduction in median time to return to usual health (hazard ratio [HR], 1.3; 95% confidence interval [CI], 1.2‒1.4; Conclusions: Patients receiving NMV/r for COVID-19 reported a reduced duration and severity of COVID-19 symptoms based on their global impression of overall symptom burden and quicker return to usual health and usual activities compared with those receiving placebo. Clinical Trial Information: ClinicalTrials.gov, NCT04960202, https://clinicaltrials.gov/study/NCT04960202.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.